- Home
- ZURA vs LUNG Comparison
ZURA vs LUNG Comparison
Compare ZURA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- LUNG
- Stock Information
- Founded
- ZURA 2022
- LUNG 1995
- Country
- ZURA United States
- LUNG United States
- Employees
- ZURA N/A
- LUNG N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- ZURA Health Care
- LUNG Health Care
- Exchange
- ZURA Nasdaq
- LUNG Nasdaq
- Market Cap
- ZURA 69.9M
- LUNG 65.6M
- IPO Year
- ZURA N/A
- LUNG 2020
- Fundamental
- Price
- ZURA $1.92
- LUNG $1.59
- Analyst Decision
- ZURA Buy
- LUNG Buy
- Analyst Count
- ZURA 10
- LUNG 7
- Target Price
- ZURA $12.67
- LUNG $7.66
- AVG Volume (30 Days)
- ZURA 309.4K
- LUNG 507.9K
- Earning Date
- ZURA 11-06-2025
- LUNG 10-29-2025
- Dividend Yield
- ZURA N/A
- LUNG N/A
- EPS Growth
- ZURA N/A
- LUNG N/A
- EPS
- ZURA N/A
- LUNG N/A
- Revenue
- ZURA N/A
- LUNG $90,549,000.00
- Revenue This Year
- ZURA N/A
- LUNG $10.30
- Revenue Next Year
- ZURA N/A
- LUNG $14.72
- P/E Ratio
- ZURA N/A
- LUNG N/A
- Revenue Growth
- ZURA N/A
- LUNG 18.24
- 52 Week Low
- ZURA $0.97
- LUNG $1.47
- 52 Week High
- ZURA $5.07
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- ZURA 53.10
- LUNG 39.01
- Support Level
- ZURA $1.97
- LUNG $1.60
- Resistance Level
- ZURA $2.19
- LUNG $1.76
- Average True Range (ATR)
- ZURA 0.12
- LUNG 0.12
- MACD
- ZURA -0.15
- LUNG 0.02
- Stochastic Oscillator
- ZURA 84.18
- LUNG 4.69
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.